Poor
Mostly Misaligned
Patient Risk:
Medium
Summary
Only a small subset of the listed claims is supported by the provided label excerpts (alcohol-avoidance timing, cognitive/neuropsychiatric expectations, and specific administration/contraindication statements). Most other claims (e.g., indications, dosing/titration and missed-dose guidance, side effect specifics like tingling/kidney stones/metabolic acidosis, interchangeability, and drug exclusivity) are not verifiable from the supplied excerpts and cannot be confirmed against the label text provided.
Category Scores
Accurate Statements
Immediate-release topiramate can cause, and therefore expected to be caused by TROKENDI XR, cognitive/neuropsychiatric adverse reactions.
Supported by section 5.7: “Immediate-release topiramate can cause, and therefore expected to be caused by TROKENDI XR, cognitive/neuropsychiatric adverse reactions.”
Alcohol use should be completely avoided within 6 hours prior to and 6 hours after TROKENDI XR administration.
Supported by section 2.4 Administration With Alcohol: “Alcohol use should be completely avoided within 6 hours prior to and 6 hours after TROKENDI XR administration.”
TROKENDI XR is contraindicated in patients with recent alcohol use (within 6 hours prior to and 6 hours after TROKENDI XR use).
Supported by section 4 Contraindications: “recent alcohol use (i.e., within 6 hours prior to and 6 hours after TROKENDI XR use)”
TROKENDI XR can be taken without regard to meals.
Supported by section 2.7 Administration Instructions: “TROKENDI XR can be taken without regard to meals.”
Swallow capsule whole and intact; do not sprinkle on food, chew, or crush.
Supported by section 2.7 Administration Instructions: “Swallow capsule whole and intact. Do not sprinkle on food, chew, or crush.”
TROKENDI XR is contraindicated in patients with a history of hypersensitivity reaction to topiramate, TROKENDI XR, or any inactive ingredients; anaphylaxis and angioedema have occurred.
Supported by section 4 Contraindications excerpt (hypersensitivity and note of anaphylaxis/angioedema).
Unsupported Statements
Trokendi XR is an extended-release form of topiramate.
Not supported by the provided label excerpts.
The '200 mg' strength refers to the dose per extended-release tablet/capsule.
Not supported by the provided label excerpts.
Trokendi XR (topiramate ER) is used for seizure disorders.
Indications section text was not provided in the supplied excerpts.
Trokendi XR (topiramate ER) is used for migraine prevention.
Indications section text was not provided in the supplied excerpts.
Trokendi XR is designed to be taken as a once-daily extended-release dose.
Dosage/frequency instructions beyond the shown excerpts were not provided.
Patients usually start at a lower dose and titrate upward to reduce side effects.
No titration/dosing regimen text was provided in the supplied excerpts.
Reaching a 200 mg dose typically occurs after gradual dose increases under clinician guidance.
No dosing regimen details were provided.
Common topiramate-related side effects can include tingling in the hands/feet.
No specific adverse reaction list text was provided in the supplied excerpts (beyond general cognitive/neuropsychiatric categories).
Common topiramate-related side effects can include dizziness.
Not supported by the provided excerpts.
Common topiramate-related side effects can include sleepiness/fatigue.
Not supported by the provided excerpts as a specific “common” side effect list; only somnolence/fatigue is mentioned within cognitive/neuropsychiatric category text without being confirmed as “common”.
Common topiramate-related side effects can include appetite/weight changes.
Not supported by the provided excerpts.
Common topiramate-related side effects can include cognitive effects such as slowed thinking.
Not supported with the “common” qualifier; the excerpt describes cognitive categories with examples but does not establish these are “common”.
Common topiramate-related side effects can include cognitive effects such as word-finding difficulty.
The excerpt includes word-finding difficulties as examples, but the “common” qualifier and general frequency are not supported by the excerpt provided.
Topiramate can carry a kidney stone risk.
Not supported by the provided excerpts.
Topiramate can cause metabolic (acid-base) problems.
Not supported by the provided excerpts.
Some side effects can be dose-related.
Not supported by the provided excerpts.
Trokendi XR is not interchangeable with immediate-release topiramate.
Not supported by the provided excerpts.
Trokendi XR should not be substituted without prescriber direction.
Not supported by the provided excerpts.
Converting between formulations depends on total daily dose and the intended release profile.
Not supported by the provided excerpts.
Missing a dose of once-daily extended-release medication can lead to breakthrough symptoms such as seizures.
No missed-dose instructions or breakthrough symptom guidance was provided.
Missing a dose of once-daily extended-release medication can lead to breakthrough symptoms such as increased migraine risk.
No missed-dose instructions or migraine-risk guidance was provided.
Label instructions typically say to take the dose when remembered unless it is close to the next dose.
No label missed-dose instructions were provided.
Patients generally should not double up after missing a dose.
No label missed-dose instructions were provided.
Drug exclusivity and patent status can affect whether lower-cost alternatives are available.
Not supported by pharmacologic prescribing information excerpts.
Contradictions
Important Omissions
Approved indications for Trokendi XR (section 1) were not provided, so indication-related claims cannot be verified against the label.
Importance:
High
Complete dosage and administration guidance (including titration, maximum dose, missed dose instructions, and dosing frequency) was not provided; several dosing claims cannot be verified.
Importance:
High
Complete boxed warnings and other warnings/precautions (section 5 beyond the shown subsections) were not provided; many safety claims cannot be verified.
Importance:
High
Full adverse reaction profile (section 6, not provided) was not provided; multiple “common side effects” claims cannot be verified.
Importance:
Moderate
Drug interaction information (section 7) was not provided; interaction-related claims cannot be assessed (though none were explicitly included in the claim list).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several statements relate to clinical use (indications, dosing/titration, missed dose consequences) and safety (side effect categories like kidney stones/metabolic issues) that are not supported by the provided label excerpts. This lack of verifiability increases the chance of material mismatch with the actual FDA-approved label content outside the supplied sections.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Misaligned
Primary Issue
Major portion of claims (especially indications, dosing/titration/missed-dose, and multiple adverse effects) are not supported by the provided label excerpts.
Suggested Improvement
Restrict statements to the exact label excerpts provided (5.7 cognitive/neuropsychiatric expectation, 2.4 alcohol avoidance timing, 4 contraindications, and 2.7 administration instructions). To evaluate other claims, provide the corresponding FDA label sections (Indications 1, Dosage/Administration 2.1-2.x including missed dose, Warnings 5 beyond 5.7, and Adverse Reactions 6).